Real-world experience with anti–programmed cell death protein 1 immunotherapy in patients with esophageal cancer: A retrospective single-center study

The “real-world” data of programmed cell death protein 1 (PD-1) inhibitors in esophageal cancer (EPC) are still an unmet medical need, including the clinical efficacy and safety. Seventy-seven EPC data were studied retrospectively; the progression-free survival (PFS), risk factors (clinical stages l...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinpeng, Cai, Lvjuan, Wu, Mengjing, Li, Guo, Zhu, Yunyun, Lin, Xinyue, Yan, Xue, Mo, Peng, Luo, Huachun, Fu, Zhichao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500415/
https://www.ncbi.nlm.nih.gov/pubmed/36158675
http://dx.doi.org/10.3389/fonc.2022.880053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500415/
https://www.ncbi.nlm.nih.gov/pubmed/36158675
http://dx.doi.org/10.3389/fonc.2022.880053

Ejemplares similares